Global Leader of Cancer Treatments
Autotelic Bio Co., Ltd. signed a contract to acquire the patent right for a targeted anti-cancer new drug technology
date : 2019-06-26
writer : admin
hits : 3519
On June 20, 2019, Autotelic Bio Co., Ltd. entered into a contract with
MRC(Medical research center for Cancer) of Chungbuk National University to acquire the patent right
for a targeted therapeutic anti-cancer new drug candidate (under development with a name of “ATB-310”).
-Signed the technology introduction contract (patent right)
for the next generation targeted therapeutic anticancer drug candidate (K284-6111)
-Obtained exclusive license for worldwide and acquired patents
-Non-clinical studies such as drug efficacy tests and pharmacological tests are planned
for various carcinoma targets.
K284-6111, an anti-cancer new drug candidate, was selected as a next-generation targeted anticancer drug
selected from 14 million candidate substances using the big data AI.
Autotelic Bio plans to carry out non-clinical studies including toxicity tests
after initial studies such as drug efficacy test and pharmacological test in various carcinomas including lung cancer.
Following the development of the immuno-anticancer drug ATB-301,
the acquisition of the new drug candidate for the targeted anticancer drug will greatly contribute
to the growth of Autotelic bio as a biotechnology company specializing in the development
of innovative anti-cancer new drugs through the expansion of the pipeline.